40.68
0.32%
-0.13
Ionis Pharmaceuticals Inc stock is currently priced at $40.68, with a 24-hour trading volume of 841.18K.
It has seen a -0.32% decreased in the last 24 hours and a -3.51% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $41.04 pivot point. If it approaches the $40.54 support level, significant changes may occur.
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Ionis Pharmaceuticals Inc (IONS) Revenue 2024
IONS reported a revenue (TTM) of $787.65 million for the quarter ending December 31, 2023, a +34.10% rise year-over-year.
Ionis Pharmaceuticals Inc (IONS) Net Income 2024
IONS net income (TTM) was -$366.29 million for the quarter ending December 31, 2023, a -35.80% decrease year-over-year.
Ionis Pharmaceuticals Inc (IONS) Cash Flow 2024
IONS recorded a free cash flow (TTM) of -$335.52 million for the quarter ending December 31, 2023, a -13.94% decrease year-over-year.
Ionis Pharmaceuticals Inc (IONS) Earnings per Share 2024
IONS earnings per share (TTM) was -$2.56 for the quarter ending December 31, 2023, a -34.74% decline year-over-year.
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
The Latest Analyst Ratings For Ionis Pharmaceuticals
Benzinga
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Zacks Investment Research
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Zacks Investment Research
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
Zacks Investment Research
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Benzinga
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Cap:
|
Volume (24h):